Psychedelics rewire Brain's learning? yale study investigates

NCT ID NCT06624137

Knowledge-focused Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This observational study at Yale University is recruiting 200 people who are already taking part in another trial where they may receive a serotonergic psychedelic (like psilocybin or LSD) or a placebo. Researchers want to understand how these substances change the brain's information processing, such as reliance on new versus old information, and electrical activity. Participants will complete computer tasks, brain scans (MEG/EEG/MRI), and interviews to track these changes over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to: If successful, this study could reveal how psychedelics alter brain processing, potentially guiding better treatments for mental health conditions and predicting who might benefit or experience side effects.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly test a therapy. Results may be complex and not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

5 people

The number who actually took part.

Started

Dec 2024

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

200 individuals who have consented to be administered serotonergic psychedelics through a clinical trial at Yale University.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participation in approved clinical protocol at Yale University involving potential administration of serotonergic psychedelics * Absence of pre-existing psychotic symptoms Exclusion Criteria: * Current intoxication based on self-report * Any neurological, medical or developmental problem that is known to impair cognition significantly based on self-report * History of seizures based on self-report * Contraindications for MR scanning including metallic implants of any kind, pacemakers and history of accidents with metal, claustrophobia (specific to those who will participate in MRI)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Addiction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alcohol abuse Behavior, Addictive combat disorder major depressive disorder migraine disorder nicotine dependence obsessive-compulsive disorder obsessive-compulsive personality disorder opiate dependence post-traumatic stress disorder substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Addiction Alcohol use disorder (AUD) Healthy volunteer Major depressive disorder (MDD) Migraine Obsessive compulsive disorder (OCD) OCD Opioid-use disorder PTSD PTSD - post traumatic stress disorder Tobacco use disorder

Psychedelics rewire Brain's learning? yale study investigates

What the study statuses mean